2015 Feb 04
Onartuzumab for Gastroesophageal Adenocarcinoma
Manish A Shah, M.D., director of gastrointestinal oncology, discusses a recent phase II study of FOLFOX with or without onartuzumab, a MET inhibitor, for the treatment of metastatic gastroesophageal adenocarcinoma. Read more





















